Last week, CMS announced that 1,750 standalone Medicare Part D prescription drug programs have enrolled in the Part D Senior Savings Model. The model is designed to help control prescription costs for seniors, capping copayments for a broad set of insulins at $35. This has been the next step in a series of ongoing policy efforts to lower drug costs—particularly the cost of insulin, which has tripled in the last decade. In 2016, individuals with Type 1 diabetes spent, on average, $5,705 on insulin, an increase of $2,841 per person since 2012. Pressure from patients to lower costs for critical medications has spurred states and private payers to cap out-of-pocket costs and provide more cost transparency. To learn more about efforts from the current Administration, government and private companies to make insulin more affordable for patients.

Open document to read more; page 3.